Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. To support rigorous… Read more




![Chemical structure of (1R,2S,3S,4R,5R)-5-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2452301-32-3-1R2S3S4R5R-5-4-chloro-3-4-S-tetrahydrofuran-3-yloxybenzylphenyl-68-dioxabicyclo3.2.1octane-234-triol.png&w=3840&q=75)
![Chemical structure of (1R,2S,3S,4S,5R)-5-(4-Chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1R2S3S4S5R-5-4-Chloro-3-4-S-tetrahydrofuran-3-yloxybenzylphenyl-68-dioxabicyclo3.2.1octane-234-triol.png&w=3840&q=75)









![Chemical structure of (2-Chloro-5-iodophenyl)[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methanone](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F915095-87-3-2-Chloro-5-iodophenyl4-3S-tetrahydro-3-furanyloxyphenylmethanone.png&w=3840&q=75)

































Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. To support rigorous pharmaceutical analysis, this category provides a comprehensive selection of reference standards, including the active pharmaceutical ingredient, critical process-related impurities, potential degradation products, and metabolites. These compounds are essential for laboratories conducting impurity profiling, method validation, and stability testing. Researchers utilize these high-quality standards—including stable isotope-labelled compounds—for precise identification and quantification in complex matrices using analytical techniques such as HPLC, LC-MS, and NMR. By providing these materials, the catalogue facilitates compliance with regulatory expectations for quality control and the toxicological evaluation of drug-related impurities during the lifecycle of the pharmaceutical product.